01 / DESIGN
What was studied?
Fasting samples from two randomized phase 2 trials underwent exploratory lipidomic and metabolomic analyses.
02 / FINDINGS
What did the researchers report?
Retatrutide was associated with changes in metabolite clusters related to fatty-acid oxidation and insulin resistance. Patterns were observed in participants with and without diabetes.
03 / LIMITS
How should it be interpreted?
These are post hoc biomarker analyses of existing trials, not independent efficacy trials. Statistical mediation does not prove a mechanism or demonstrate fewer cardiovascular events.
Loti Labs Peptide editorial reading note. Based on the linked source record. Methods and corrections.